Outlook Therapeutics Partners with Syner-Med for ONS-5010 Launch
Ticker: OTLK · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, commercialization, drug-development
TL;DR
Outlook Therapeutics teams up with Syner-Med to get their new eye drug, ONS-5010, ready for market.
AI Summary
Outlook Therapeutics, Inc. announced on April 1, 2024, that it has entered into a strategic collaboration with Syner-Med, Inc. to support the commercialization of its investigational ophthalmic medicine, ONS-5010. This collaboration aims to leverage Syner-Med's expertise in market access and patient support programs to prepare for the potential launch of ONS-5010.
Why It Matters
This partnership is crucial for Outlook Therapeutics as it brings in specialized expertise to navigate market access and patient support, which are critical for the successful commercialization of their new drug.
Risk Assessment
Risk Level: medium — The company is still in the process of commercializing an investigational drug, which carries inherent risks related to regulatory approval and market adoption.
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- Syner-Med, Inc. (company) — Collaboration Partner
- ONS-5010 (drug) — Investigational Ophthalmic Medicine
- April 1, 2024 (date) — Date of Report
FAQ
What is the primary purpose of the collaboration between Outlook Therapeutics and Syner-Med?
The primary purpose is to support the commercialization of Outlook Therapeutics' investigational ophthalmic medicine, ONS-5010, by leveraging Syner-Med's expertise in market access and patient support programs.
What is the name of the investigational drug being discussed?
The investigational drug is ONS-5010.
What specific areas of expertise does Syner-Med bring to this collaboration?
Syner-Med brings expertise in market access and patient support programs.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on April 1, 2024.
What is the business address of Outlook Therapeutics?
The business address of Outlook Therapeutics is 485 Route 1 South, Building F, Suite 320, Iselin, New Jersey 08830.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-04-02 16:15:28
Key Financial Figures
- $1.00 — Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company
Filing Documents
- tm2410459d1_8k.htm (8-K) — 22KB
- 0001104659-24-042515.txt ( ) — 192KB
- otlk-20240401.xsd (EX-101.SCH) — 3KB
- otlk-20240401_pre.xml (EX-101.PRE) — 22KB
- otlk-20240401_lab.xml (EX-101.LAB) — 33KB
- tm2410459d1_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On April 1, 2024, Outlook Therapeutics, Inc. (the "Company") received written notice (the "Compliance Notice") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on The Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from March 14, 2024 to March 28, 2024, the closing bid price of the Company's common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: April 2, 2024 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer